Kato, Chihiro
Fujii, Naohiko
Miyakoshi, Chisato
Asada, Shinji http://orcid.org/0000-0002-7717-8945
Onishi, Yoshihiro
Fukuma, Shingo
Nomura, Takanobu
Wada, Michihito
Fukagawa, Masafumi
Fukuhara, Shunichi
Akizawa, Tadao
Article History
Received: 25 February 2020
Accepted: 2 October 2020
First Online: 12 October 2020
Ethics approval and consent for participate
: The study protocol was approved by the central ethics committee at Kobe University’s School of Medicine. Informed consent was not mandatory according to the ethical guidelines for epidemiological research in Japan. Anonymized data was collected and analyzed. The study is registered at ClinicalTrials.gov (NCT00995163).
: Not applicable.
: CK, SA, TN and MW are employees of Kyowa Kirin Co. ltd., (KKC). NF received grants from KKC. CM and YO do not have any conflicts of interest to declare. SF1 has acted as a scientific advisor for KKC. SF2 has acted as a scientific advisor for and has received grants from KKC. MF has received consulting fees from KKC and Ono Pharmaceutical; lecture fees from KKC, Bayer, Torii Pharmaceutical and Ono Pharmaceutical; and grants from KKC, Bayer and Ono Pharmaceutical. TA has received personal fees from KKC, Astellas Pharma, Bayer, Fuso Pharmaceutical, Japan Tobacco, Ono Pharmaceutical, NIPRO, Chugai Pharmaceutical, Kissei Pharmaceutical, Torii Pharmaceutical and Otsuka Pharmaceutical.